About G&N

Our Culture

It is extremely exciting to see G&N continue to innovate and augment its technologies, offering and customer base. As well as continuing to lead the market in DVT prevention across the UK, proudly supporting both the NHS and private healthcare sectors. G&N has most recently expanded the product portfolio to include a new woundcare and prevention division. This latest category of products adds to the existing specialisms across; medical compression, clinical waste containment and treatment, colorectal scopes, retractable needles, laboratory consumables and rehabilitation devices. These additions are set to bolster our central mission of enhancing patient care and outcomes.

G&N now supplies end users and distributors in 27 countries in our main markets of Europe, Middle East and Australasia. G&N is registered on US GPO frameworks and is actively seeking opportunities to grow that distribution network with like-minded international partners.

These continued efforts underscore our dedication to not only advancing healthcare but also protecting our planet.

The Team

Senior Leadership

Giles GriffithsChief Executive Officer

Personal Statement – “At G&N, we are dedicated to revolutionising the healthcare industry by supplying innovative best in class products and technology that enhance patient outcomes and minimise environmental impact. We also take great pride in our exceptional team. Through strategic recruitment and the continuous development of existing talent, we continue to cultivate a dynamic group of professionals. Each team member brings unique value, fostering a collaborative environment that benefits both colleagues and customers alike.”

Karl BarrettFinance & Operations Director

Personal Statement – “As a commercially minded, Finance & Ops Director, I bring a wealth of experience in driving financial and operational value across the business. By working closely with senior stakeholders and partners I enjoy helping the wider team to bring new products to market, boosting sales, optimising costs, and enhancing earnings. At G&N, I am dedicated to investing in and developing our talented team, ensuring every product, employee and idea thrives and ultimately makes a positive clinical difference at scale. By thinking critically and aligning key objectives, I like to lead with a focus on sustainable growth and exceptional value for our customers and partners.”

Andrea GardnerHead of Sales

Personal Statement – “My background in nursing provides me with an acute understanding of the challenges and pressures faced daily by healthcare professionals. This firsthand experience fuels my passion for alleviating their stress through innovative solutions that enhance patient care. I am dedicated to ensuring that our products and technologies support better patient outcomes and streamline healthcare processes. At G&N, I am proud to lead a team that shares this commitment to excellence, working tirelessly to deliver solutions that truly make a difference. ”

Dr. Neil ConroyHead of QA/RA | Technical Lead Quality and Regulatory

Personal Statement – “With extensive experience in quality assurance and a strong background in biotechnology and engineering, I am committed to maintaining the highest standards at G&N. My role involves ensuring that every product meets rigorous quality benchmarks, providing our customers with reliable and innovative healthcare solutions. I work closely with our teams to streamline processes, identify improvements, and implement best practices. I am dedicated to upholding the strongest commitment to quality, ensuring excellence in every aspect of our technical delivery and operations.”

Simon SáFeioMarketing & Communications Director

Personal Statement – “I draw on two decades of experience to combine best practice with innovative ideas, collaboration and talent development to drive meaningful results. I’m passionate about positioning G&N as a leader in key specialist clinical fields, and more importantly ensuring our communication strategies help healthcare professionals to improve patient care. My goal is to bring products to market that genuinely make a difference, supporting G&N’s mission to improve the lives of millions everyday.”

About G&N

Where we are now?

G&N continues to be market leader for DVT prevention in the UK, actively supplying the NHS and private healthcare markets. We have expanded our product portfolio to include colorectal scopes, medical compression garments, retractable needles and pressure relieving devices, which have become a core focus for our business in the coming year.

G&N now supplies end users and distributors in 27 countries in our main markets of Europe, Middle East and Australasia. G&N are registered on US GRO frameworks and we are actively seeking opportunities to grow that distribution network with like-minded international partners.

G&N is actively looking for new product opportunities in the UK market and encourages suppliers to work with us on their new innovations to further improve the clinical outcomes for both patients and healthcare professionals.

G&N’s laboratory divisions is moving to greener initiatives including improved sustainable clinical waste containment and environmentally beneficial waste treatment systems.

THE G&N TIMELINE

How did we get here?

2024
Wound Care - Launch of a G&N specialist wound care & prevention division featuring key products including the NEXA Device which uses NPWT and offers the opportunity for patients to transition from hospital to home more quickly and reducing the risk of re-admission. The device delivers the performance and flexibility of durable medical equipment (DME) NPWT systems (by storing fluid remotely) but in a disposable device.
2023
Bevelled Proctolux - Addition of the Proctolux range of single use, fully disposable and self-illuminating Proctoscopes for use in diagnosis and treatment of the anal cavity and rectum. The Proctolux features the revolutionary designed and patented “Clear View System” which protects the light guide to give a clear and unobstructed view of the examination area.
2022
CTC-7 - Roll-out of the CTC-7 Device, an iceless and portable all in one rehabilitation system for athletes recovering from sports injuries and for patients’ post-operative recovery. The CTC-7 offers all-in-one cryotherapy, thermotherapy, and contrast therapy treatments.
2021
Griff Pac - Launch of The Griff® Pac, a high-quality clinical waste box that is 74% lighter than standard rigid units.

Made from lightweight corrugated polypropylene and approved to UN 3291, its ‘fold flat’ design reduces transport and treatment costs, whilst the low plastic content ensures that processing emissions are minimised.
2020
G&N launched our online retail store www.fitlegs.com, providing compression to the community and healthcare professionals for their day to day use. Conducting campaigns providing free socks to NHS staff throughout the pandemic to support those on the front line. Our FITLEGS 2 product was listed for prescription on the NHS FP10 Drug Tariff.
2019
Expanded our FITLEGS compression hosiery range, bringing out FITLEGS 2 our class 2 medical range for those that clinically require higher strength compression therapy.
2018
G&N expanded the product portfolio acquiring the Proctolux and Sigmolux scopes range; along with the introduction of Vanish Point a range of retractable needles. At the same time G&N moved the waste containment business into a Laboratory division to better serve our customers and develop technologies and products that are required for a more sustainable future.
2017
G&N introduced the Geko device to the market, this revolutionary innovation provides electro stimulation to the perineal nerve to improve blood flow. This addition completed G&N’s DVT prophylaxis portfolio, providing a complete offering of solutions in an acute hospital setting.
2016
G&N expanded the FITLEGS product range. Developing FITLEGS Everyday & Life, for those that seek everyday compression to reduce aches and pains in the legs and feet; FITLEGS Sport for those looking to improve endurance and recovery.
2015
After 6 more years of supplying to the NHS and continuous product innovation, the birth of FITLEGS, G&N’s compression hosiery brand became market leaders, obtaining 60% of the UK Anti-Embolism stocking market.
2009
G&N’s AES range supplied 25% of the UK market. We expanded our DVT prevention portfolio with PneumaPress an intermittent pneumatic compression device, gaining a respectable market share within an acute hospital setting.
2006
G&N started the journey of transitioning into a global medical device company. Started the development of the Anti Embolism Stocking range, exploiting a gap in the market for a new innovative product.
2000
G&N expanded the clinical waste range to offer various other containment solutions, thus becoming the provider of the largest range in the UK.
1994
Giles Griffiths became CEO of G&N, and the company moved into the clinical waste market offering a range of Griff bins to NHS for clinical waste disposal.
1980
G&N expanded the range of laboratory consumables by becoming distributors to Sterilin.
1974
G&N Started by Graham Griffiths and Bent Nielsen as a laboratory business, manufacturing and selling petri dishes alongside other lab consumables.

How can we be of assistance?

Please complete the form and one of our team members will respond as soon as possible.